Dialysis rooms to offer Pomegranate juice

Health Care 133 Comments

Patients on hemodialysis consuming a moderate amount of pomegranate juice for a year can lead to a continuous, cumulative, beneficial effect on their lipid profile, their blood pressure, and the number of antihypertensive medications they are on as per Dr Batya Kristal, from the Nephrology Department at the Western Galilee Hospital in Nahariya, Israel who was talking at the American Society of Nephrology 44th Annual Meeting. In addition to water, sugars, and pectin, pomegranates contain the antioxidants ascorbic acid and polyphenolic flavonoids.

In the study, hemodialysis patients were randomized to receive 100 mL of pomegranate juice (n = 66) or an equivalent-tasting placebo (n = 35) 3 times a week for 12 months.

  • At 12 months, all components of the lipid profile improved in the pomegranate juice group but not in the placebo group.
  • In the juice group, there were statistically significant decreases in TGs from baseline to 12 months
    (P = .01), especially in patients with a baseline TG level of at least 200 mg/dL (P < .001).
  • HDL rose significantly (P = .005) in the juice group. There was no significant change in any of these parameters in the placebo group.
  • There was a significant decrease in systolic blood pressure in the juice group overall (P < .006), especially in patients who had a baseline systolic pressure of at least 140 mm Hg (P < .005); this was not the case in the placebo group.
  • At 12 months, those in the juice group were taking significantly fewer antihypertensive drugs than those in the placebo group (P < .05).
  • In the juice group, 22% of the subjects were taking fewer and 12.2% were taking more anti-hypertensive drugs; in the placebo group, 7.7% were taking fewer and 34.6% were taking more antihypertensive drugs.
  • Pomegranate juice contains a high level of potassium, so potassium overload is a risk.
  • Pomegranate juice intake can interfere with the metabolism of certain drugs.